Skip to main content

Table 2 Antifungal use among hospitals based on patient group

From: Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America

Antifungal agent Neonates: n = 54;
100,155 admissions
Pediatrics: n = 44;
159,936 admissions
Adults: n = 60;
1,841,667 admissions
ANOVA (F-statistic)
Total antifungals* 14.4 (10.7 to 18.2) 75.8 (56.6 to 95.1) 73.2 (62.7 to 84.4) p < 0.001 (34.8)
Azoles* 12.3 (8.6 to 15.6) 54.6 (40.8 to 68.4) 55.1 (47.2 to 63.4) p < 0.001 (32.7)
 Fluconazole 12.2 (8.8 to 15.6) 40.6 (31.7 to 49.4) 37.9 (33.3 to 42.4)  
 Voriconazole 0.03 (− 0.03 to 0.09) 12.5 (6 to 19) 10 (7.8 to 12.3)  
 Posaconazole 0 0.91 (− 0.02 to 1.8) 5.8 (3.4 to 8.3)  
 Itraconazole 0 0.61 (0.12 to 1.1) 1.3 (0.58 to 2.1)  
Amphotericin B* 1.4 (0.71 to 2.1) 3.8 (1.9 to 5.7) 3.9 (3.0 to 4.8) p = 0.0021 (6.1)
 Conventional 0.66 (0.23 to 1.1) 0.78 (− 0.07 to 1.6) 1.3 (0.76 to 1.9)  
 Liposomal 0.25 (0.03 to 0.47) 2.3 (0.72 to 3.9) 2.1 (1.5 to 2.6)  
 Lipid complex 0.5 (−0.018 to 1.02) 0.72 (− 0.002 to 1.43) 0.5 (0.24 to 0.78)  
Echinocandins* 0.76 (0.32 to 1.2) 17.4 (11.4 to 23.5) 14.3 (11.8 to 16.8) p < 0.001 (28)
 Caspofungin 0.17 (−0.005 to 0.34) 4.9 (0.5 to 9.3) 2.9 (1.2 to 4.6)  
 Micafungin 0.59 (0.21 to 0.98) 12.5 (7.3 to 17.8) 10.4 (7.9 to 12.9)  
 Anidulafungin 0 0 1 (0.4 to 1.7)  
  1. ANOVA, analysis of variance
  2. All data presented as mean (95% CI) days of therapy/1000 patient days
  3. *Mean days of therapy/1000 patient days was statistically different between the neonatal group and the adult and pediatric group on post-hoc Tukey analysis, all p < 0.01, no significant differences occurred between the pediatric and adult groups, all p > 0.12